Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Psychotropic drugs in breast milk: no evidence for adverse effects on prepulse modulation of startle reflex or on cognitive level in infants.

Developmental psychobiology·1998

Same author

Fluoxetine in breast-milk and developmental outcome of breast-fed infants.

The British journal of psychiatry : the journal of mental science·1998

Same author

Human brain tumors and exposure to metal and non-metal elements: a case-control study.

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer·1998

Same author

Rehospitalisation for asthma within 12 months: unequal rates on the basis of gender in two hospitals.

Australian and New Zealand journal of medicine·1998

Same author

Asthma prevalence, morbidity and management practices in South Australia, 1992-1995.

Australian and New Zealand journal of medicine·1998

Same author

Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.

Psychological medicine·1998

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

ASCPT Task Force for advancing pharmacometrics and integration into drug development.

M J Goldberger¹, N Singh, S Allerheiligen

¹Abbott, Rockville, Maryland, USA.

Clinical Pharmacology and Therapeutics

|July 22, 2010

Summary

This summary is machine-generated.

Pharmacometrics offers powerful methods for drug development and regulatory decisions, demonstrating significant benefits in clinical trials. The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Task Force aims to accelerate its adoption and impact.

Related Experiment Videos

Last Updated: Jun 10, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Area of Science:

Pharmacometrics
Clinical Pharmacology
Drug Development

Background:

Traditionally, medical and biostatistical experts validated pharmaceutical testing.
Pharmacometrics offers advanced approaches for drug development and regulatory decision-making.
Published case studies highlight pharmacometrics' significant contributions to decision-making.

Purpose of the Study:

To build on existing momentum and accelerate the dissemination of pharmacometrics' impact.
To promote the adoption of pharmacometrics in drug development.
To outline the contributions of pharmacometrics and the specific goals of the ASCPT Task Force.

Main Methods:

Review of existing literature and case studies on pharmacometrics.
Analysis of economic and public health benefits of pharmacometrics in clinical trials.
Description of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Task Force's objectives.

Main Results:

Pharmacometrics provides powerful tools supporting critical drug development and regulatory decisions.
The economic and public health benefits of implementing pharmacometrics in clinical trials are substantial.
Numerous studies confirm the value of pharmacometrics in guiding pharmaceutical development.

Conclusions:

Pharmacometrics significantly enhances the validity of pharmaceutical testing and decision-making.
The ASCPT Task Force seeks to broaden the integration of pharmacometrics into drug development processes.
Accelerating the adoption of pharmacometrics offers considerable economic and public health advantages.